Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

After hours: March 27 at 7:59:30 PM EDT Loading Chart for JNJ ...

Tesla and SpaceX CEO Elon Musk clarified that he uses only "a small amount once every other week or something like that" ...